Hyperhomocysteinemia and Risk Factors for CVD

Hyperhomocysteinemia and its Relations to Conventional Risk Factors for Cardiovascular Diseases in Adult Nigerians: The REMAH Study.

Short title: Hyperhomocysteinemia and Risk Factors of CVD

Babangida S. Choria, Benjamin Danlad, Bassey A. Inyang, Michael P. Okoh, Maxwell M. Nwegbu, Adewale L. Alli, Augustine N. Odili

aDepartment of Medical Biochemistry, Faculty of Basic Medical Sciences, College of Health Sciences, University of Abuja, Abuja, Nigeria

bCirculatory Health Research Laboratory, College of Health Sciences, University of Abuja, Abuja, Nigeria

cDepartment of Chemical Pathology, Faculty of Basic Clinical Sciences, University of Abuja, College of Health Sciences, Abuja, Nigeria
Correspondence to:
Augustine Nonso Odili, MD, PhD,
Circulatory Health Research Laboratory,
College of Health Sciences
University of Abuja,
Old Anatomy Block, Beside School of Nursing,
University of Abuja Teaching Hospital,
Gwagwalada,
Abuja, Nigeria

Telephone: +2348185173193 (office)
+2348033954983 (mobile)
email: augustine.odili@uniabuja.edu.ng
odilimercy@yahoo.com
Abstract

**Background:** Evidence linking homocysteine (Hcy) with cardiovascular diseases (CVD) or its risk factors are insufficient in a Sub-Saharan black population.

**Objective:** We set out to evaluate the association between Hcy and hypertension and other CVD risk factors in a population of adult Nigerians.

**Methods:** Data of 156 adults aged 18-70 years was accessed from the North Central study site of the REMoving the MAsk on Hypertension (REMAH) study. Homocysteine, blood glucose and lipid profile in whole blood/serum were measured using standard laboratory methods. Hypertension was diagnosed if average of 5 consecutive blood pressure (BP) measurements obtained using a mercury sphygmomanometer was equal to or higher than 140 systolic and/or 90 mmHg diastolic or the individual is on antihypertensive medication. Hyperhomocysteinemia (HHcy) was defined as Hcy>10µmol/L.

**Results:** Of the 156 participants, 72 (43.5%) were hypertensive, of whom 18 had HHcy. Subjects with HHcy were significantly (p<0.05) older (41.5 vs 40.6yrs), had lower HDL-cholesterol (0.6 vs 0.8mmol/L) and higher systolic (145.5 vs 126.0mmHg) and diastolic BP (92.9 vs 79.6mmHg), compared to those without HHcy. Intake of alcohol and a 1yr increase in age were respectively and significantly (p<0.05) associated with a 1.54 and 0.10 µmol/L increase in Hcy. In a multivariable model adjusted for age, sex and body mass index, a 1µmol/L increase in Hcy, was associated with a 1.69 mmHg and 1.34 mmHg increase in systolic and diastolic pressure (p<0.0001) respectively; and a 0.01mmol/L decrease in HDL-cholesterol (p<0.05).

**Conclusion:** HHcy occurs among hypertensive Nigerians and it is independently associated with age, HDL-cholesterol, systolic and diastolic BP.

**Key Words:** Hyperhomocysteinemia, High-Density Lipoprotein, Blood Pressure, Cardiovascular Diseases Risk Factors
Introduction

Hypertension is a global health challenge increasingly responsible for most deaths worldwide. According to the Global Disease Burden survey\(^1\), cardiovascular diseases (CVD) account for nearly 17 million deaths annually, of which more than 50% are due to hypertension related complications\(^2\).

In its effort to tackle the rising burden of hypertension globally, the World Health Organisation recommends increase in physical activity, avoidance of unhealthy diet, reduction in salt intake and abstinence from tobacco use and harmful intake of alcohol. Despite adopting these recommendations at population and individual levels, the burden of hypertension and other CVDs remains inadequately addressed, thus underscoring the need to explore other risk factors such as homocysteine.

Homocysteine is an intermediary metabolite of methionine whose amount in excess of 10µmol/L (otherwise known as hyperhomocysteinemia) increases the risk of CVD in people with hypertension\(^3\). Compelling evidence from large-scale observational\(^4\) and longitudinal studies\(^5\) indicate that the risk of stroke in subjects suffering from hypertension accompanied by HHcy is higher compared to those with neither/either of the two conditions. Epidemiological data from United States of America, China and Europe indicate that among hypertensive subjects, prevalence of HHcy are 39%, 75%, and 19% respectively. Although the role of homocysteine is well-established in the development of vascular diseases\(^6,7\), efforts to use it as a therapeutic target of hypertension or CVD has suffered major setbacks\(^8,9\). Hypothesis stimulated by recent evidence\(^10\) indicates that the therapeutic benefit of homocysteine lowering may be affected by its interaction with other risk factors of hypertension or CVD, hence may
vary from population to population. In Nigeria, 38% of its adult population are hypertensive, of whom control of blood pressure is achieved only in 12% and knowledge of the burden of hyperhomocysteinemia is uncertain. The present study was aimed at evaluating the burden of hyperhomocysteinemia among adult Nigerians and also to assess the relation of homocysteine with hypertension and established risk factors of CVD.

**Methods**

Participants:

Participants of the current study were of a sub-sample of adult Nigerians aged 18 years and above that participated in the Removing the Mask on Hypertension (REMAH) Study\textsuperscript{11,12}. REMAH was a nationwide study that surveyed hypertension and its risk factors in the six geopolitical zones of Nigeria. From each zone, subjects were drawn from two communities of a state including Anambra, Akwa-Ibom, Oyo, Zamfara, Gombe and FCT-Abuja using a multistaged sampling technique. Communities were sensitized and mobilised, following which houses systematically numbered, randomly selected and visited to issue invitations to eligible adults aged 18 years and above. Physical examinations were conducted on consenting participants further to which blood samples were collected for biochemical examinations. REMAH strictly complied with the Helsinki Guidelines\textsuperscript{13} for conducting research on human subjects. For the purpose of this homocysteine sub-study, a total of 156 subjects with complete data were selected from the FCT-Abuja study site using a systematic random technique. Subjects were excluded if they were on folic acid, vitamin B6, vitamin B12 supplementation or any lipid lowering medications.
**Biochemical Examination**

Non-fasting blood samples were collected and the resulting sera stored at -20°C until analysis. Homocysteine was estimated from blood serum using the sandwich enzyme-linked immunoabsorbent (ELISA) assay method of Engvall and Perlmann\(^{14}\). Random blood glucose was measured from whole blood using accuchek glucometer\(^{\circ}\). Other biochemical analytes including total cholesterol, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and triacylglycerol (TAG) were estimated at the Circulatory Health Research Laboratory using Landwind c100\(^{\circ}\) autochemistry analyser. Analyses were done using ready-to-use reagents obtained from Beijing Strong Biotechnologies incorporation, Haidan District, Beijing China in accordance with manufacturer’s guide.

**Blood Pressure Measurement**: Blood pressure was obtained by trained observers using Accoson\(^{\circ}\) mercury sphygmomanometer. Observers received training on blood pressure measurement using the British Hypertension Society Blood Pressure Measurement Educational Video\(^{15}\). They measured brachial blood pressure by auscultation of the Korotkoff sounds at the non-dominant arm in accordance with the 2013 guidelines of the European Society of Hypertension(ESH)/European Society of Cardiology (ESC)\(^{16}\). Participants were allowed to sit and rest for 5 minutes after which 5 BP readings are obtained at an interval of 30 to 60 seconds. Systolic and phase V diastolic blood pressures are determined to the nearest 2 mm Hg. Standard cuffs with 12 x 24 cm inflatable bladders are used for subjects whose arm circumference is less than 31cm, and 15 x 35cm for those with arm circumference greater than 31cm. A participant’s clinic BP was the average of the 5 consecutive BP measurements.
Definition of Terms:

Hypertension was defined according to the 2013 ESH/ESC guidelines\textsuperscript{16} as systolic blood pressure $\geq$ 140 mm Hg and/or diastolic blood pressure $\geq$ 90 mm Hg and/or self-reported treatment of hypertension using antihypertensive medications.

Hyperhomocysteinemia was defined according to the American Heart Association/ American Stroke Association Council on Stroke as a serum homocysteine greater than 10$\mu$mol/L\textsuperscript{17}.

Other measurements: Field officers measured weight and height in Kilogram and centimeter respectively, using a stadiometer. Waist and hip circumference were measured in centimeter using a non-stretchable tape. They also administered a modified WHO STEPs Questionnaire to collect information on relevant medical history, alcohol and cigarette consumption, and intake of medications.

Database management and statistical analysis

We used SAS software version 9.4 (SAS Institute, Cary, NC) for data management and statistical analysis. We used mean and standard deviation to respectively measure the central tendency and dispersion of continuous variables. Differences of means between binary groups were tested using student t-test. We used numbers and percentages to express categorical variables and differences in percentages were tested using chi-square. We regressed serum homocysteine on biochemical, anthropometric, socio-demographic and physiological characteristics to determine their associations. We further tested for Independent association of serum homocysteine with other variables in a multivariable model adjusted for age, sex and BMI. The null hypothesis was rejected for 2-sided values of $P < 0.05$. 

\[ \text{ } \]
Results

Characteristics of Study Participants

Table 1 shows the baseline characteristics of subjects stratified based on their hyperhomocysteinemia status. A total of 156 subjects with an average age of 41.5 years were included in this study. Of the entire subjects, 72 (46.2%) were women, 84 (53.9%) were men and 18 (11.5%) had hyperhomocysteinemia. In comparison to subjects without hyperhomocysteinemia, subjects with hyperhomocysteinemia had significantly higher (p<0.05) mean age (49.0 vs 35.0yrs), higher mean systolic (145.5 vs 126.0mmHg), higher mean diastolic blood pressure (92.9 vs 79.6mmHg) and lower HDL-C (0.6 vs 0.8mmol/L).

Prevalence of Hyperhomocysteinemia

Hyperhomocysteinemia (HHcy) was prevalent in 11.5% of the overall subjects; 13.1% in men, 9.7% in women and 23.6% in subjects with hypertension (Figure 1).

Association of Homocysteine with Sociodemographic Characteristics

According to table 2, homocysteine (Hcy) correlated positively with age and alcohol intake. Intake of alcohol and a 1year increase in age were significantly (p<0.05) associated with 1.54 and 0.10 µmol/L increase in Hcy respectively. In a multivariable model, mutually adjusted for age, sex and BMI, the relationship remained the same only for age (Table 3).

Association of Homocysteine with Biochemical Characteristics

A 1 µmol/L increase in Hcy associated positively with triacylglycerol (β=0.03, p=0.0252) and negatively with HDL-C (β=-0.02, p=0.0166). The relationship between Hcy and HDL-C remained the same after adjustment for age, sex and BMI.
Association of Homocysteine with Blood Pressure

Increasing Hcy by 1 µmol/L was associated with a corresponding increase of 2.2mmHg in systolic blood pressure (SBP) and 1.7mmHg in diastolic blood pressure (DBP). Adjustment for age, sex and BMI did not alter the association of Hcy and systolic or diastolic BP.
Discussion

The main finding of this study is that hyperhomocysteinemia (HHcy) occurred in nearly one-eighth of the overall subjects and one-quarter of the hypertensive subjects. Homocysteine (Hcy) independently associated with age, high-density lipoprotein cholesterol (HDL-C), systolic and diastolic blood pressure.

Due to the use of different cut-offs for HHcy in different studies, it is difficult to discuss our findings in the light of those of other studies. Our decision to use the 10 µmol/L threshold was driven by expert opinions which suggest that commencement of Hcy reduction at this level is more beneficial than at higher levels. Previous studies of HHcy among hypertensive Nigerians were hospital-based and were done using a threshold of 15 µmol/L. The prevalence of HHcy among hypertensive subjects in the current study (23.6%) was strikingly lower than the 1956.0% and 2098.3% reported by the previous studies. It is highly probable that difference in study participants may account for this wide difference bearing that subjects of the current study were drawn from a semi-urban general population whose socio-economic status can afford them a vitamin-rich diet well known to protect against HHcy. Vitamin B6, B12 and folic acid are essential requirements of Hcy metabolism which when deficient, precipitates an elevation in plasma Hcy. Other reports across the globe had shown that among hypertensive populations, HHcy occurs 75.0% in China, 39.4% in the United States of America and 18.7% in Europe. In addition to diet, other factors directly influencing plasma Hcy concentration are enzymes responsible for Hcy metabolism such as methylene tetrahydrofolate reductase (MTHFR) and cystathionine beta synthase (CBS) whose defective or variant forms could be
involved in geographical/racial with phenotypic variation of HHcy prevalence. In the Hordaland homocysteine study including over 18,000 adult Norwegians aged at least 40 years, low folate status accompanied by Hcy>40 µmol/L and attributable to the MTHFR 677C >T polymorphism was prevalent in over 78% of the study participants.

The relation of Hcy with lipid fractions remains largely inconsistent across various observational and experimental studies. Nevertheless, some of the earlier results were in concordance with our findings. Evidence from a cross-sectional survey of 4,660 Chinese subjects in Shijingshan district of Beijing, showed that increasing Hcy was associated with an increased risk of low HDL-C (AOR=1.41, 95%CI:1.14-1.73) and hypertriglyceridemia (AOR=1.29, 95%CI: 1.10-1.52). In 300 Indian patients with coronary heart disease, Mahalle and colleagues reported that Hcy was directly proportional to TAG and VLDL but inversely proportional to HDL-C. Experimental studies involving the use of double knock-out mice model (CBS -/-/apo-E-) with reduced CBS activity showed lower HDL-C (19.9mg/dl vs 24.4mg/dl) and higher Hcy (210 µM vs 3.8µM) when compared with single knock-out (CBS +/-/apo-E-)24. The mechanism underlying the unfavourable association of Hcy with lipid fractions involves various transcription factors and enzymes of lipid metabolism including peroxisome proliferator-activated receptor alpha (PPARα), lecithin-cholesterol acyl transferase (LCAT) and sterol regulatory element binding proteins (SREBPs). Hcy interrupts the transcriptional activities of PPARα, thereby down regulating the production of apo-AI which is an indispensable component of HDL-C production and biological activity. It is also most probable Hcy interruption/disruption plays some significant roles in the co-regulation of some downstream retrotransposons such as,
transposable elements (TEs), repetitive sequences in mammalian genomes, which have been implicated in many of the same conditions for which PPAR agonists are therapeutic, including conditions such, neurodegeneration, schizophrenia, and drug addiction. Furthermore, Hcy also interferes with HDL-C production by inhibiting the activity of LCAT\textsuperscript{30,31} which is essential for reverse cholesterol transport. Conversely, Hcy enhances the expression of SREBPs, a membrane bound transcriptional factor of the endoplasmic reticulum which encodes enzymes of cholesterol/TAG metabolism and uptake\textsuperscript{32}. These biochemical mechanisms explaining the interaction between Hcy and lipid metabolism are consistent with the results of this study.

Though there are mixed views concerning the link between Hcy and blood pressure\textsuperscript{10,25,33-35}, various mechanisms in support of a positive association have been put forward \textsuperscript{6,36,37}. Under conditions of HHcy, uptake and synthesis of cysteine (an essential precursor of glutathione) is reduced and antioxidant potential compromised thus leading to oxidative stress\textsuperscript{38}. Additionally, Hcy is also metabolised into Hcy-thiolactone, a reactive specie which when bound to collagen, inhibits its activity\textsuperscript{7}. The resultant effect of these is endothelial damage, endothelium-myocyte uncoupling, hindered passage of nitric oxide through the matrix barrier, poor vasodilation, diastolic dysfunction and high blood pressure\textsuperscript{6,36}. Other possible mechanisms include increased arterial stiffness, increased arteriolar constriction, increased sodium reabsorption, poor elastic vascular wall and smooth cell proliferation\textsuperscript{6}. In a case-controlled study involving 2,615 Chinese subjects, Yang and colleagues\textsuperscript{10} observed a strong positive correlation between Hcy and blood pressure ($P<0.05$). Similarly, report from the third National Health
and Nutrition Examination Survey (NHANES III) including 7,612 United States residents aged 17 and above, showed that after adjusting for CVD risk factors, a 5µmol/L increase in Hcy was associated with a 0.7mmHg and 0.5mmHg increase in systolic and diastolic BP in men and a 1.2mmHg and 0.7mmHg increase in systolic and diastolic BP in women. Contrary to these, the Framingham Heart Survey, documented that after a median follow up 2,104 subjects for 4 years, the age and sex-adjusted odds of hypertension incidence due to Hcy was negative and non-significant.

Positive association of Hcy with age or alcohol intake have been widely reported. Though the mechanism underlying this association is vague, it is hypothesized that deficiency in folate, vitamin B12, metabolic changes, poor nutritional absorption and organ function associated with ageing or alcohol intake are possible causes of this anomaly.

In conclusion, HHcy occurs among adult Nigerians living with hypertension. Hcy associates independently with age, HDL-C, office systolic and diastolic BP. Our findings suggest that Hcy directly or indirect contributes to increasing blood pressure, possibly mediating some of these undesirable effects through disturbance of normal HDL-C and or TAG metabolism. These findings also support the need for future research to conduct a pre-assessment of study population with a view to discovering the presence of interaction effects of Hcy and conventional risk factors on hypertension or CVD.

Despite conflicting evidence regarding the CVD benefit of lowering plasma Hcy, which has hindered global adoption of Hcy guidelines in CVD care, routine assessment of Hcy in hypertensive subjects is necessary as emerging evidence.
indicate that Hcy attenuates the efficacy of certain antihypertensive medications like angiotensin converting enzyme inhibitors.

**Strengths and Limitations**

Given the small size of our sample, caution may be required when translating our findings to the general adult population of Nigeria. However, our subjects were drawn from a well-delineated area of Abuja, a cosmopolitan city with ethnically diverse population that has a semblance of the general Nigerian population. Our study was cross-sectional in design, hence the cause-effect association of Hcy with other factors could not be ascertained.
Legend to figures

Figure 1: Prevalence of hyperhomocysteinemia

Abbreviations

AOR  Adjusted odds ratio
BMI  Body mass index
CBS  Cystathionine β-synthase
CI  Confidence interval
CVD  Cardiovascular diseases
DBP  Diastolic blood pressure
FCT-Abuja  Federal capital territory-Abuja
Hcy  Homocysteine
HDL-C  High-density lipoproteins
HHcy  Hyperhomocysteinemia
LCAT  Lecithin-cholesterol acyl transferase
LDL-C  Low-density lipoproteins
MTHFR  Methylene tetrahydrofolate reductase
OR  Odds ratio
PPARα  Peroxisome proliferator-activated receptor α
SBP  Systolic blood pressure
SREBPs  Sterol regulatory element binding proteins
REMAH  REmoving the MAask on Hypertension
TAG  Triacylglycerol
NHANES III  National health and Nutrition examination survey III
VLDL  Very low-density lipoproteins
Declaration

Acknowledgement

The authors gratefully acknowledge the effort of Mrs. Maureen Amaechi who provided valuable administrative and clerical support to the REMAH project.

Source of funding

This research was funded by the Tertiary Education Trust Fund (TETFUND) National Research Fund (NRF batch IV)

Ethics approval and consent to participate

All participants gave informed consent to participate and the study was approved by the University of Abuja Teaching Hospital Ethical research committee.

Competing Interest

None of the authors declares a conflict of interest

Consent for publication

Not applicable

Availability of Data and Materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ Contributions

The study was conceptualized and designed by Odili AN, Alli LA and Chori BS. Data collection was conducted and overseen by Chori BS, Odili AN, Danladi B and Nwegbu MM. Manuscript was written by Chori BS and revised by Odili AN, Alli LA, Okoh MP and Inyang BA. Final manuscript was thoroughly read and approved by all authors.
### Table 1. Baseline Characteristics of Participants

|               | Overall | Hcy<10µmol/L | Hcy>10µmol/L | p-Value |
|---------------|---------|--------------|--------------|---------|
| **Number (%)** | 156     | 138 (88.5)   | 18 (11.5)    |         |
| Women         | 72(46.2)| 65 (90.3)    | 7 (9.7)      | 0.5109  |
| Men           | 84(53.9)| 73 (86.9)    | 11 (13.1)    |         |

### Mean ± SD

|                        | Overall | Hcy<10µmol/L | Hcy>10µmol/L | p-Value |
|------------------------|---------|--------------|--------------|---------|
| **Age**                | 41.5±13.6| 40.6±12.9    | 48.0±17.0    | 0.0247  |
| **BMI, Kg/m²**         | 25.5±5.2| 25.5±5.1     | 25.4±6.4     | 0.9674  |
| **WHR**                | 0.89±0.09| 0.89±0.09    | 0.89±0.07    | 0.9957  |
| **Systolic BP**        | 128.2±20.9| 126.0±20.0  | 145.5±20.3   | <0.0001 |
| **Diastolic BP**       | 81.1±13.7| 79.6±13.2    | 92.9±11.6    | <0.0001 |
| **Random blood glucose**| 5.98±2.08| 6.0±2.0      | 5.9±2.4      | 0.7735  |
| **HDL-C, mmol/L**      | 0.78±0.38| 0.8±0.4      | 0.6±0.4      | 0.0103  |
| **LDL-C, mmol/L**      | 2.04±0.98| 2.0±1.0      | 2.2±1.0      | 0.5124  |
| **TAG, mmol/L**        | 1.42±0.68| 1.4±0.7      | 1.5±0.4      | 0.6315  |
| **Total Cholesterol, mmol/L** | 3.47±1.06| 3.5±1.0      | 3.4±1.0      | 0.8738  |

**Diabetes Mellitus**: fasting or random blood glucose >7mmol/L or 11.1mmol/L respectively or use of antidiabetic medication

**Hypertension**: systolic BP ≥140mmHg and/or diastolic BP ≥90mmHg or use antihypertensive medication
Table 2. Univariate Linear Regression Analysis of Association of Homocysteine with Sociodemographic, Anthropometric, Biochemical and Physiological Characteristics

|                           | β value | P value |
|---------------------------|---------|---------|
| **Socio-demographic**     |         |         |
| Age                       | 0.097   | 0.0005  |
| Sex                       | 1.015   | 0.1856  |
| Cigarette smoking         | 1.755   | 0.2215  |
| Alcohol intake            | 1.542   | 0.0442  |
| Body Mass Index           | 0.083   | 0.3449  |
| Waist-hip ratio           | 0.002   | 0.3200  |
| **Biochemical**           |         |         |
| LDL                       | 0.007   | 0.6824  |
| HDL-C                     | -0.015  | 0.0166  |
| TAG                       | 0.026   | 0.0252  |
| Total Cholesterol         | 0.003   | 0.8568  |
| Blood Glucose             | 0.044   | 0.2148  |
| **Physiological**         |         |         |
| Systolic BP               | 2.220   | <0.0001 |
| Diastolic BP              | 1.564   | <0.0001 |
| Pulse rate                | 0.353   | 0.1179  |
Table 3. Multivariable Linear Regression Analysis of Association of Homocysteine with Socio-demographic, Biochemical and Physiological Characteristics

| Characteristics   | β value | P value |
|-------------------|---------|---------|
| **Sociodemographic** |         |         |
| Age               | 0.095   | 0.0008  |
| Alcohol Intake    | 1.091   | 0.1488  |
| **Biochemical**   |         |         |
| HDL-C             | -0.014  | 0.0368  |
| TAG               | 0.015   | 0.1832  |
| **Physiological** |         |         |
| Systolic BP       | 1.692   | <0.0001 |
| Diastolic BP      | 1.340   | <0.0001 |

*Adjusted for age, sex and BMI
Figure 1. Prevalence of Hyperhomocysteinemia
Hyperhomocysteinemia and Risk Factors for CVD

References

1. Causes of Death 2008. 2008. (http://www.who.int/healthinfo/global_burden_disease/cod_2008_sources_methods.pdf).
2. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224-2260.
3. Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015;14:6.
4. Wu Y, Huxley R, Li L, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and Health Survey 2002. Circulation. 2008;118(25):2679-2686.
5. Towfighi A, Markovic D, Ovbiagele B. Pronounced association of elevated serum homocysteine with stroke in subgroups of individuals: a nationwide study. Journal of the neurological sciences. 2010;298(1-2):153-157.
6. van Guldener C, Nanayakkara PW, Stehouwer CDJChr. Homocysteine and blood pressure. 2003;5(1):26.
7. Perla-Kajan J, Utyro O, Rusek M, Malinowska A, Sitkiewicz E, Jakubowski H. N-Homocysteinylatation impairs collagen cross-linking in cystathionine beta-synthase-deficient mice: a novel mechanism of connective tissue abnormalities. FASEB J. 2016;30(11):3810-3821.
8. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354(15):1578-1588.
9. Investigators HOPEH. Homocysteine Lowering with Folic Acid and B Vitamin in Vascular Disease. 2006 343 2006.
10. Yang B, Fan S, Zhi X, et al. Interactions of homocysteine and conventional predisposing factors on hypertension in Chinese adults. J Clin Hypertens (Greenwich). 2017;19(11):1162-1170.
11. Augustine N. ODILI BSC, Benjamin DANLADI, Peter C. NWAKILE, Innocent C. OKOYE, Umar ABDULLAH, Maxwell N. NWEGBU, Kefas ZAWAYA, Ime ESSIEN, Kabiru SADA, John O. OGEDENGBE, Akinyemi AJE, Godsent ISIGUZO. Prevalence, Awareness, Treatment and Control of Hypertension in Nigeria: Data from a nationwide survey 2017. Glob Heart. 2020;15(1):47.
12. Nwakile PC, Chori BS, Danladi B, et al. Removing the mask on hypertension (REMAH) study: Design, quality of blood pressure phenotypes and characteristics of the first 490 participants. Blood Press. 2019:1-10.
13. World Medical Association Declaration of Helsinki: Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects. JAMA; 3/19/1997, 1997.
14. Engvall E, Perlmann P. Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes. J Immunol. 1972;109(1):129-135.
15. BHS DVD on BP Measurement. 2007; https://bihsoc.org/wp-content/uploads/2017/10/BHS-DVD.avi.
16. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-2219.
17. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from
the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease. *Circulation.* 2006;113(10):e409-e449.

18. McCully KS. Homocysteine, vitamins, and vascular disease prevention. *Am J Clin Nutr.* 2007;86(5):1563s-1568s.

19. Ajuluchukwu A, Oluwatowoju I, Adebayo K, Onakoya AJWJLSMR. Plasma Total Homocysteine in Diverse Cardiovascular Diseases in Urban Africans. 2011;1:126-132.

20. Onyemelukwe OU, Maiha BB. Prevalence of hyperhomocysteinemia, selected determinants and relation to hypertension severity in Northern-Nigerian hypertensives: the ABU homocysteine survey. *Ghana Med J.* 2020;54(1):17-29.

21. Guo S, Pang H, Guo H, et al. Ethnic differences in the prevalence of high homocysteine levels among low-income rural Kazakh and Uyghur adults in far western China and its implications for preventive public health Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease. *Int J Environ Res Public Health.* 2015;12(5):5373-5385.

22. de Bree A, van der Put NM, Mennen LI, et al. Prevalences of hyperhomocysteinemia, unfavorable cholesterol profile and hypertension in European populations. *European journal of clinical nutrition.* 2005;59(4):480-488.

23. Ilhan N, Kucuksu M, Kaman D, Ilhan N, Ozbay Y. The 677 C/T MTHFR polymorphism is associated with essential hypertension, coronary artery disease, and higher homocysteine levels. *Arch Med Res.* 2008;39(1):125-130.

24. Wang H, Jiang X, Yang F, et al. Hyperhomocysteinemia accelerates atherosclerosis in cystathionine beta-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation. *Blood.* 2003;101(10):3901-3907.

25. Refsum H, Nurk E, Smith AD, et al. The Hordaland Homocysteine Study: A Community-Based Study of Homocysteine, Its Determinants, and Associations with Disease. *The Journal of Nutrition.* 2006;136(6):1731S-1740S.

26. Yadav AS, Bhagwat VR, Rathod IM. Relationship of plasma homocysteine with lipid profile parameters in ischemic heart disease. *Indian J Clin Biochem.* 2006;21(1):106-110.

27. Momin M, Jia J, Fan F, et al. Relationship between plasma homocysteine level and lipid profiles in a community-based Chinese population. *Lipids Health Dis.* 2017;16(1):54.

28. Mahalle N, Kulkarni MV, Garg MK, Naik SS. Vitamin B12 deficiency and hyperhomocysteinemia as correlates of cardiovascular risk factors in Indian subjects with coronary artery disease. *J Cardiol.* 2013;61(4):289-294.

29. Mikael LG, Genest J, Jr., Rozen R. Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. *Circ Res.* 2006;98(4):564-571.

30. Namekata K, Enokido Y, Ishii I, Nagai Y, Harada T, Kimura H. Abnormal lipid metabolism in cystathionine beta-synthase-deficient mice, an animal model for hyperhomocysteinemia. *J Biol Chem.* 2004;279(51):52961-52969.

31. Velez-Carrasco W, Merkel M, Twiss CO, Smith JD. Dietary methionine effects on plasma homocysteine and HDL metabolism in mice. *J Nutr Biochem.* 2008;19(6):362-370.

32. Horton JD, Shimomura I. Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis. *Curr Opin Lipidol.* 1999;10(2):143-150.

33. McMahon JA, Skeaff CM, Williams SM, Green TJ. Lowering Homocysteine with B Vitamins Has No Effect on Blood Pressure in Older Adults. The Journal of Nutrition; 5/1/2007, 2007.
34. Sundström J, Sullivan L, D’Agostino RB, et al. Plasma homocysteine, hypertension incidence, and blood pressure tracking: the Framingham Heart Study. *Hypertension.* 2003;42(6):1100-1105.

35. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. *Circulation.* 1997;96(6):1745-1749.

36. C.Tyagi USaS. Homocysteine and Hypertension in Diabetes: Does PPAR? Have a Regulatory Role? *PPAR Research.* 2010;2010.

37. Stehouwer CD, van Guldener Cjcc, Medicine L. Does homocysteine cause hypertension? 2003;41(11):1408-1411.

38. Veeranki S, Tyagi SC. Defective homocysteine metabolism: potential implications for skeletal muscle malfunction. *Int J Mol Sci.* 2013;14(7):15074-15091.

39. Lim U, Cassano PA. Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994. *Am J Epidemiol.* 2002;156(12):1105-1113.

40. Janson JJ, Galarza CR, Murua A, et al. Prevalence of hyperhomocysteinemia in an elderly population. *Am J Hypertens.* 2002;15(5):394-397.

41. El-Sammak M, Kandil M, El-Hifni S, Hosni R, Ragab M. Elevated plasma homocysteine is positively associated with age independent of C677T mutation of the methylenetetrahydrofolate reductase gene in selected Egyptian subjects. *Int J Med Sci.* 2004;1(3):181-192.

42. Halsted CH, Villanueva JA, Devlin AM, Chandler CJ. Metabolic interactions of alcohol and folate. *J Nutr.* 2002;132(8 Suppl):2367S-2372S.

43. Qin X, Li Y, Sun N, et al. Elevated Homocysteine Concentrations Decrease the Antihypertensive Effect of Angiotensin-Converting Enzyme Inhibitors in Hypertensive Patients. *Arterioscler Thromb Vasc Biol.* 2017;37(1):166-172.